
**Disclaimer**  

EN: This MD file was generated automatically through conversion of the HTML source served by the Federal Publishing Platform [Fedlex](https://www.fedlex.admin.ch/).
During this process, certain elements of the original source such as footnotes, tables or pictures can be lost or transformed incorrectly. Any inaccuracies present in the HTML source will be carried over to the MD file.  

DE: Diese MD Datei wurde durch automatische Konvertierung des auf der Publikationsplattform des Bundes [Fedlex](https://www.fedlex.admin.ch/) publizierten HTML Quelltextes erstellt.
Dieser Konvertierungsprozess kann dazu führen, dass gewisse Elemente wie bspw. Fussnoten, Tabellen oder Bilder falsch dargestellt werden oder verloren gehen.
Allfällige inkorrekte Passagen im HTML Quelltext werden in die MD Datei übernommen.  

EN: This is not an official publication. Only the official publication by the [Federal Chancellery](https://www.bk.admin.ch/bk/en/home.html) is authorative and legally binding.  
DE: Dies ist keine amtliche Veröffentlichung. Massgebend ist allein die Veröffentlichung durch die [Bundeskanzlei](https://www.bk.admin.ch/bk/de/home.html).  
FR: Ceci n’est pas une publication officielle. Seule la publication opérée par la [Chancellerie fédérale](https://www.bk.admin.ch/bk/fr/home.html) fait foi.  
IT: presente documento non è una pubblicazione ufficiale. Fa unicamente fede la pubblicazione della [Cancelleria federale](https://www.bk.admin.ch/bk/it/home.html).  

&nbsp;

----

&nbsp;

810.306

English is not an official language of the Swiss Confederation. This translation is provided for information purposes only and has no legal force.

# Ordinance on Clinical Trials with Medical Devices

## (ClinO-MD)

of 1 July 2020 (Status as of 26 May 2021)

The Swiss Federal Council,

based on the Human Research Act of 30 September 2011 (HRA)  
and on Articles 54 paragraphs 3, 6 and 8, 54*b* paragraphs 2 and 3 and 82   
of the Therapeutic Products Act of 15 December 2000 (TPA),

ordains:

# [Chapter 1 General Provisions](https://www.fedlex.admin.ch/eli/cc/2020/553/en#chap_1)

## [Section 1 Subject matter, Definitions and Applicable Provisions](https://www.fedlex.admin.ch/eli/cc/2020/553/en#chap_1/sec_1)

[**Art. 1** Subject matter](https://www.fedlex.admin.ch/eli/cc/2020/553/en#art_1) 

[1] This Ordinance shall regulate:


|    a. the requirements pertaining to clinical trials with medical devices and other devices in accordance with Article 1 of the Medical Devices Ordinance of 1 July 2020 (MedDO);  
|    b. the approval and reporting procedures for clinical trials involving the devices in accordance with letter a;  
|    c. the duties and responsibilities of research ethics committees (Ethics Committees), the Swiss Agency for Therapeutic Products (Swissmedic) and the Federal Office of Public Health (FOPH) in connection with the approval and reporting procedures;  
|    d. the registration of clinical trials involving devices in accordance with letter a;  
|    e. public access to information concerning clinical trials.

[2] In this Ordinance, the term *devices* is used to designate all products defined in paragraph 1 letter a.

[**Art. 2** Definitions](https://www.fedlex.admin.ch/eli/cc/2020/553/en#art_2) 

The following definitions shall apply in this Ordinance:


|    a. *clinical trial* means the systematic investigation of a device involving one or more persons for the purpose of assessing the safety or performance of the device;  
|    b. *conformity-related clinical trial* means a clinical trial conducted to demonstrate the conformity of the device being investigated;  
|    c. *contracting state* means any state that is bound to mutually recognise conformity assessments and conformity procedures for devices by an agreement with Switzerland under international law based on equivalent legislation;  
|    d. *sponsor* means any individual or institution or organisation that takes responsibility for the initiation of a clinical trial – specifically its instigation, management and financing – in Switzerland;  
|    e. *investigator* means any individual responsible for the conduct of a clinical trial and for the protection of the participants at a clinical trial site; any participant who assumes responsibility for initiating a clinical trial in Switzerland is simultaneously the trial’s sponsor.

[**Art. 3** Applicable provisions](https://www.fedlex.admin.ch/eli/cc/2020/553/en#art_3) 

[1] The following provisions of the Ordinance of 20 September 2013 on Clinical Trials in Human Research (ClinO) apply to clinical trials with devices:


|    a. for scientific integrity and scientific quality: Articles 3 and 4 ClinO;  
|    b. for participant information, consent and withdrawal of consent: Articles 7–9 ClinO;  
|    c. for liability and indemnification: Article 10 paragraphs 1 letter c and 2 and Article 11–14 ClinO;  
|    d. for the conduct of clinical trials in emergency situations: Articles 15–17 ClinO;  
|    e. for the storage of personal health data and biological material: Article 18 ClinO;  
|    f. for inspections and administrative measures: Article 46 paragraphs 1, 2, 4 and 5 and Article 47 and 48 ClinO.

[2] The powers exercised by Swissmedic and the duty to cooperate and provide information incumbent on the sponsor and investigator in the event of inspections and administrative measures are governed *mutatis mutandis* by Articles 77 and 78 MedDO.

[3] Clinical trials with in vitro diagnostic devices, devices as specified in Art. 2*a* paragraph 2 TPA or combinations as specified in Article 2 paragraph 1 letters f and g MedDO are subject to ClinO.

## [Section 2 General Obligations of the Sponsor and Investigator and Professional Qualifications](https://www.fedlex.admin.ch/eli/cc/2020/553/en#chap_1/sec_2)


[**Art. 4** General obligations of the sponsor and investigator](https://www.fedlex.admin.ch/eli/cc/2020/553/en#art_4) 

[1] The sponsor and investigator must conduct clinical trials in accordance with Article 72 and Chapters I and III of Annex XV to Regulation (EU) 2017/745 on medical devices (EU-MDR).

[2] Compliance with the requirements of paragraph 1, specified in greater detail by designated technical standards or common specifications in accordance with Article 9 paragraph 1 EU-MDR, is presumed if the clinical trial is conducted in accordance with those standards or specifications. Article 6 paragraph 5 MedDO applies *mutatis mutandis*.

[3] If the sponsor is not domiciled in Switzerland and does not have a place of business there, it must designate an agent that is domiciled or has a place of business in Switzerland as an address for correspondence. This agent must ensure compliance with the sponsor’s obligations.

[**Art. 5** Professional qualifications](https://www.fedlex.admin.ch/eli/cc/2020/553/en#art_5) 

[1] Clinical trial investigators must:


|    a. be entitled to practise independently as a doctor or in another profession that specifically qualifies them to conduct the clinical trial;  
|    b. demonstrate adequate knowledge of the internationally recognised requirements for the conduct of clinical trials and the specialist knowledge and experience required for the clinical trial; and  
|    c. possess knowledge of the legal requirements governing clinical trials or be able to guarantee the availability of such knowledge by recruiting appropriate expertise.

[2] The remaining people conducting the clinical trial must possess the training or experience in the specialist field that is required to conduct clinical trials.

# [Chapter 2 Approval and Reporting Procedures](https://www.fedlex.admin.ch/eli/cc/2020/553/en#chap_2)

## [Section 1 General Provisions](https://www.fedlex.admin.ch/eli/cc/2020/553/en#chap_2/sec_1)

[**Art. 6** Categorisation of clinical trials](https://www.fedlex.admin.ch/eli/cc/2020/553/en#art_6) 

[1] Clinical trials fall into category A if: 


|    a. the device to be investigated carries a conformity marking in accordance with Article 13 MedDO;   
|    b. the device to be investigated is used in accordance with the instructions for use; and  
|    c. it is not prohibited to make the device to be investigated available on the market, put it into service or use it in Switzerland.

[2] Category A clinical trials are divided into sub-categories as follows:


|    a. if the participants do not undergo additional invasive or stressful procedures compared with the procedures applied when the device is used under normal conditions: sub-category A1;  
|    b. if the participants undergo additional invasive or stressful procedures compared with the procedures applied when the device is used under normal conditions: sub-category A2.

[3] Clinical trials fall into category C if:


|    a. the device carries a conformity marking in accordance with Article 13 MedDO but is not used in accordance with the instructions for use (sub-category C1);  
|    b. the device does not carry a conformity marking in accordance with Article 13 MedDO (sub-category C2); or  
|    c. it is prohibited to make the device available on the market, put it into service or use it in Switzerland (sub-category C3).

[**Art. 7** Exemption from mandatory approval](https://www.fedlex.admin.ch/eli/cc/2020/553/en#art_7) 

Category A clinical trials are exempt from the requirement to obtain approval from Swissmedic set out in Article 54 paragraph 1 TPA.

[**Art. 8** Data processing in electronic systems and information sharing](https://www.fedlex.admin.ch/eli/cc/2020/553/en#art_8) 

[1–5] ...

[6] The medical devices information system in accordance with Article 62*c* TPA and the information system operated by the Cantons in accordance with Article 56*a* HRA may contain information on administrative or criminal proceedings or sanctions concerning the sponsor, investigator or manufacturer that Swissmedic and the competent Ethics Committee require in order to fulfil their duties under this Ordinance.

[7] Swissmedic shall, upon request, forward the highly sensitive data in accordance with paragraph 6 to the Ethics Committees.

[**Art. 9** Information and coordination for approval procedures](https://www.fedlex.admin.ch/eli/cc/2020/553/en#art_9) 

The competent Ethics Committee and Swissmedic shall provide information to each other on the following aspects and coordinate their assessments:


|    a. categorisation of the clinical trial in accordance with Article 6;  
|    b. aspects concerning the review areas in accordance with Article 11 and Article 17;  
|    c. the conduct of the procedures set out in Articles 12 and 19 and in Chapter 3.

## [Section 2 Procedures to be performed by the Competent Ethics Committee](https://www.fedlex.admin.ch/eli/cc/2020/553/en#chap_2/sec_2)


[**Art. 10** Application](https://www.fedlex.admin.ch/eli/cc/2020/553/en#art_10) 

[1] The sponsor shall submit the application documents specified in Annex 1.

[2] The Ethics Committee may demand additional information.

[3] The investigator may submit the application in place of the sponsor. In this case, it assumes the duties of the sponsor as set out in Articles 14 and 15 and the duty to notify and report to the competent Ethics Committee. The sponsor must co-sign the application documents.

[**Art. 11** Review areas](https://www.fedlex.admin.ch/eli/cc/2020/553/en#art_11) 

The areas to be reviewed by the Ethics Committee are governed by Article 25   
ClinO.

[**Art. 12** Procedures and time limits](https://www.fedlex.admin.ch/eli/cc/2020/553/en#art_12) 

[1] The Ethics Committee shall confirm receipt of the application to the sponsor within 10 days and notify the sponsor of any formal shortcomings in the application documents. It shall give the applicant 10 days to rectify the shortcomings and inform the applicant that it will not admit the application if the shortcomings are not rectified within the deadline.

[2] It shall make its decision within 40 days of confirming receipt of the formally correct application documents. 

[3] If the Ethics Committee demands additional information in accordance with Article 10 paragraph 2, the 40-day period shall be paused until the information is received.

[**Art. 13** Multi-centre clinical trials](https://www.fedlex.admin.ch/eli/cc/2020/553/en#art_13) 

[1] The sponsor shall submit its application for a multi-centre clinical trial in accordance with Article 47 paragraph 2 HRA to the Ethics Committee responsible for the coordinating investigator. The coordinating investigator may submit the application in place of the sponsor. Article 10 paragraph 3 applies *mutatis mutandis*.

[2] The coordinating investigator is the person with responsibility in Switzerland for coordinating the investigators responsible for the various trial sites.

[3] The Lead Committee shall confirm receipt of the application to the sponsor within 10 days and notify it of any formal shortcomings in the application documents. It shall give the applicant 10 days to rectify the shortcomings and inform the applicant that it will not admit the application if the shortcomings are not rectified within the deadline. Upon application, the Lead Committee may extend these deadlines by a period of five days in each case.

[4] It shall notify the Ethics Committees responsible for the trial sites (participating Ethics Committees) that it has received the application. These shall review the local conditions and notify the Lead Committee of their evaluation within 15 days.

[5] The Lead Committee shall make its decision within 40 days of confirming receipt of the formally correct application documents.

[**Art. 14** Procedure for investigations involving radiation sources](https://www.fedlex.admin.ch/eli/cc/2020/553/en#art_14) 

[1] For investigations involving radiation sources, the sponsor shall submit the additional application documents specified in Annex 1 number 4. The approval procedure shall be governed by Articles 10–13 and 15, subject to the paragraphs below.

[2] The sponsor shall submit the additional application documents specified in Annex 1 number 5 if the effective dose, taking account of the uncertainty factor, exceeds 5mSv per person and year and:


|    a. the trial involves a radiopharmaceutical that is not authorised in Switzerland;  
|    b. the trial involves a radiopharmaceutical that is authorised in Switzerland but does not involve a routine nuclear medical investigation; or  
|    c. the trial involves a different radioactive source.

[3] The Ethics Committee shall forward the application documents to the FOPH in accordance with Annex 1 number 5.

[4] The FOPH shall send the Ethics Committee its comments on compliance with radiological protection legislation and on the estimated dose. It may grant exemptions to the reporting obligation in accordance with Article 39 paragraph 5.

[5] The Ethics Committee shall approve the trial if:


|    a. the requirements set out in Article 11 are fulfilled; and  
|    b. the FOPH has not submitted any objections to the clinical trial within a reasonable period.

[6] It shall notify the FOPH of its decision.

[**Art. 15** Amendments](https://www.fedlex.admin.ch/eli/cc/2020/553/en#art_15) 

[1] All amendments to an approved clinical trial that could have a significant impact on the safety, health or rights of participants and on the robustness or reliability of the clinical data obtained (substantial amendments) must be approved by the Ethics Committee prior to their adoption. This obligation does not extend to measures that have to be taken immediately to protect trial participants.

[2] The sponsor shall submit any application documents specified in Article 10 paragraph 1 that are affected by the amendment. Amendments must be clearly marked. The sponsor shall submit information on the nature of and reasons for the amendment at the same time.

[3] The Ethics Committee shall issue its decision on substantial amendments within 30 days. Article 12 applies *mutatis mutandis*. 

[4] Where a further clinical trial site is to be added and that site lies outside the competence of the Ethics Committee that approved the clinical trial, the procedure set out in Article 13 applies *mutatis mutandis*.

[5] Other amendments must be reported to the Ethics Committee with the annual safety report as specified in Article 35.

[6] For clinical trials in sub-category A2, the sponsor shall also notify the contracting states in which the clinical trial is being conducted or is due to be conducted of the nature of and reasons for the amendments; it shall attach the documents as specified in Annex 1 which are affected by the amendments.

## [Section 3 Approval Procedures to be performed by Swissmedic](https://www.fedlex.admin.ch/eli/cc/2020/553/en#chap_2/sec_3)


[**Art. 16** Application](https://www.fedlex.admin.ch/eli/cc/2020/553/en#art_16) 

[1] The sponsor shall submit the application documents specified in Annex 1 number 2.

[2] Swissmedic may demand additional information.

[3] If the sponsor withdraws its application for conformity-related clinical trials in sub-categories C1 and C2 before Swissmedic has made a decision, it shall inform the contracting states in which the clinical trial is being conducted or is due to be conducted.

[**Art. 17** Review areas](https://www.fedlex.admin.ch/eli/cc/2020/553/en#art_17) 

[1] For clinical trials, Swissmedic shall verify:


|    a. whether the application is complete;  
|    b. whether the requirements of Article 54 paragraph 4 letter b TPA are fulfilled.

[2] It shall conduct a simplified review if the sponsor demonstrates the following in its application:


|    a. the clinical trial falls into sub-category C1 or C2 and involves a non-invasive device classified as class I or IIa under Article 15 MedDO;  
|    b. use of the device to be investigated entails at most minimal risk for the trial participants;  
|    c. the investigator has signed a written agreement with the sponsor requiring the investigator to notify the sponsor without delay of serious adverse events or any other incident as specified in Article 32;  
|    d. the sponsor operates a risk management and safety monitoring system.

[3] Swissmedic shall restrict its simplified review to determining whether the application is complete and the evidence required under paragraph 2 has been provided.

[**Art. 18** Clinical trials with devices capable of emitting ionising radiation](https://www.fedlex.admin.ch/eli/cc/2020/553/en#art_18) 

[1] The additional application documents specified in Annex 1 numbers 4 and 5 must be submitted for category C clinical trials.

[2] Swissmedic shall invite the FOPH to submit its comments before it approves trials. The FOPH shall review compliance with radiological protection legislation and the estimated dose.

[3] Swissmedic shall approve the trial if:


|    a. the requirements set out in Article 17 are fulfilled; and  
|    b. the FOPH has not submitted any objections to the clinical trial within an appropriate period.

[4] It shall notify the FOPH of its decision.

[**Art. 19** Procedures and time limits](https://www.fedlex.admin.ch/eli/cc/2020/553/en#art_19) 

[1] Swissmedic shall confirm receipt of the application to the sponsor within 10 days and notify it of any formal shortcomings in the application documents. It shall give the applicant 10 days to rectify the shortcomings and inform the applicant that it will not admit the application if the shortcomings are not rectified within the deadline. Upon application, Swissmedic may extend the deadline for rectifying the shortcomings by 20 days.

[2] It shall make its decision within 45 days of confirming receipt of the formally correct application documents. It may only approve a clinical trial if the competent Ethics Committee has approved it beforehand.

[3] Swissmedic shall also inform the contracting states if it rejects the application.

[4] If a device is being used in humans for the first time or manufactured using a new process, Swissmedic may extend the period specified in paragraph 2 by no more than 20 days. It shall notify the sponsor of the extension.

[5] If Swissmedic demands additional information as specified in Article 16 paragraph 2, the 45-day period shall be paused until the information is received.

[**Art. 20** Amendments](https://www.fedlex.admin.ch/eli/cc/2020/553/en#art_20) 

[1] Substantial amendments to an approved clinical trial, in accordance with Article 15 paragraph 1, must be submitted to Swissmedic for approval prior to their adoption. This obligation does not extend to measures that have to be taken immediately to protect trial participants. 

[2] The sponsor shall submit to Swissmedic the application documents as specified in Article 16 paragraph 1 that are affected by the amendment. It shall submit information on the nature of and reasons for the amendment at the same time.

[3] Swissmedic shall make its decision within 38 days of receiving all the application documents affected by the amendment. Article 19 applies *mutatis mutandis*. This period may be extended by seven days.

[4] Other amendments applicable to the application documents submitted to Swissmedic must be notified to Swissmedic as quickly as possible.

[4bis] For conformity-related clinical trials in sub-categories C1 and C2 that are also being conducted or are also due to be conducted in EU or EEA states, the sponsor shall notify Swissmedic of the nature of and reasons for substantial amendments to the clinical trial in EU or EEA states that affect the protocol, investigational device or instructions for use for the investigational device.

[5] The sponsor of a conformity-related clinical trial in sub-categories C1 and C2 shall also notify the contracting states in which the clinical trial is being conducted or is due to be conducted of the nature of and reasons for the amendments; it shall attach the documents as specified in Annex 1 which are affected by the amendments.

# [Chapter 3 Coordinated Assessment Procedure](https://www.fedlex.admin.ch/eli/cc/2020/553/en#chap_3)

[**Art. 21–31**](https://www.fedlex.admin.ch/eli/cc/2020/553/en#art_21__31_)

# [Chapter 4 Documentation, Notifications and Reporting](https://www.fedlex.admin.ch/eli/cc/2020/553/en#chap_4)

## [Section 1 Documentation and Reporting of Incidents and of Safety and Protection Measures](https://www.fedlex.admin.ch/eli/cc/2020/553/en#chap_4/sec_1)



[**Art. 32** Documentation of adverse events](https://www.fedlex.admin.ch/eli/cc/2020/553/en#art_32) 

[1] The sponsor must document the following adverse events that occur during a clinical trial in a standardised form:


|    a. adverse events of all types designated in the protocol as crucial to assessing the results of the clinical trial;  
|    b. all serious adverse events:  
|    c. any device deficiency that could have resulted in serious adverse events under less propitious circumstances or if appropriate action or an intervention had not taken place;  
|    d. all new findings relating to a documented incident as specified in letters a–c. 

[2] The sponsor shall provide Swissmedic and the competent Ethics Committee with the documentation specified in paragraph 1 upon request.

[3] The definitions of adverse events and device deficiencies are those in Article 2 numbers 57–59 EU-MDR.

[**Art. 33** Reporting of serious adverse events](https://www.fedlex.admin.ch/eli/cc/2020/553/en#art_33)

[1] For category C clinical trials, the sponsor shall notify Swissmedic and the competent Ethics Committee without delay of:


|    a. each serious adverse event that has a causal relationship with the investigational device, the comparator device or a test procedure or where a causal relationship appears entirely possible;  
|    b. any device deficiency that could have resulted in serious adverse events under less propitious circumstances or if appropriate action or an intervention had not taken place;  
|    c. all new findings relating to a reported incident as specified in letters a and b.

[1bis] For conformity-related clinical trials in sub-categories C1 and C2 that are also being conducted abroad, the sponsor shall also notify Swissmedic and the competent Ethics Committee without delay of all incidents, device deficiencies and findings as specified in paragraph 1 which arise from the conduct of the clinical trial abroad.

[2] To ensure reporting is not delayed, the sponsor may provisionally submit an incomplete report. 

[3] For conformity-related clinical trials in sub-categories C1 and C2, the sponsor shall also provide reports in accordance with paragraph 1 to those contracting states in which the clinical trial is being conducted or is due to be conducted

[4] For category A clinical trials, the sponsor shall report:


|    a. to the competent Ethics Committee: without delay any serious adverse event for which a causal relationship between the event and the test procedure used in the clinical trial has been ascertained; paragraph 2 is applicable;  
|    b. to Swissmedic and the competent Ethics Committee: the reports as specified in Articles 87–90 EU-MDR.

[**Art. 34** Reporting of safety and protective measures](https://www.fedlex.admin.ch/eli/cc/2020/553/en#art_34) 

[1] If safety and protective measures have to be implemented without delay during the course of a clinical trial, the sponsor shall report these measures and the circumstances that necessitated them to the Ethics Committee within two days.

[1bis] For clinical trials that are also being conducted or are also due to be conducted in EU or EEA states, the sponsor shall also notify the Ethics Committee within two days of all prescribed or voluntary safety and protective measures that are being implemented in EU or EEA states and the circumstances that necessitated them.

[2] The sponsor must report any clinical trial that is terminated or interrupted for reasons of safety in accordance with Article 36 paragraph 4.

[3] For category C clinical trials, reporting under paragraphs 1 and 1bis must also be submitted to Swissmedic.

[4] For conformity-related clinical trials in sub-categories C1 and C2, the sponsor shall also provide reports under paragraph 1 to the contracting states in which the clinical trial is being conducted or is due to be conducted

## [Section 2 Reporting on the Safety of Participants and Reporting at the Conclusion, Termination or Interruption of a Clinical Trial](https://www.fedlex.admin.ch/eli/cc/2020/553/en#chap_4/sec_2)


[**Art. 35** Annual reporting on the safety of participants](https://www.fedlex.admin.ch/eli/cc/2020/553/en#art_35) 

[1] Once a year, the sponsor shall submit to the competent Ethics Committee a list of the serious adverse events and device deficiencies in accordance with Article 33 and provide it with a report on their severity, causal relationship with the device and the intervention, as well as on the safety of the participants (Annual Safety Report, ASR).

[2] For category C clinical trials that are also being conducted abroad, the list and report must also include adverse events and device deficiencies that occurred abroad.

[2bis] For category C clinical trials that are also being conducted in, or are also due to be conducted in, EU or EEA states, the report in accordance with paragraph 2 must include the status of the clinical trial in the states in question.

[**Art. 36** Reporting the conclusion, termination and interruption of a clinical trial](https://www.fedlex.admin.ch/eli/cc/2020/553/en#art_36) 

[1] The sponsor shall report the conclusion of the clinical trial in Switzerland to the Ethics Committee within 15 days.

[2] Unless otherwise specified in the protocol, the conclusion of the clinical trial is deemed to be the final visit by the final participant.

[3] The sponsor shall report the termination or interruption of the clinical trial to the Ethics Committee within 15 days. The report must set out the reasons for the termination or interruption.

[4] If the trial is terminated or interrupted for reasons of safety, the following shall apply:


|    a. The report must be submitted within 24 hours.  
|    b. The report must also be submitted to those contracting states in which the clinical trial is being conducted or is due to be conducted.

[4bis] For clinical trials that are also being conducted in EU or EEA states, the sponsor must also report any termination or interruption of the trial in EU or EEA states to the Ethics Committee within 24 hours if the termination or interruption was for reasons of safety.

[5] If a multi-centre clinical trial is terminated or interrupted at one of the trial sites, the sponsor must also perform the reporting according to paragraph 3 and 4 to the other participating Ethics Committees.

[**Art. 37** Final report](https://www.fedlex.admin.ch/eli/cc/2020/553/en#art_37) 

[1] The sponsor shall submit to the Ethics Committee a final report in accordance with Section 2.8 of Chapter I and Section 7 of Chapter III of Annex XV to EU-MDR:


|    a. within one year of the clinical trial being concluded;  
|    b. within three months of the clinical trial being terminated or interrupted.

[2] If scientific reasons prevent compliance with the reporting deadline specified in paragraph 1 letter a, the sponsor must submit the report as soon as it is available. The protocol must specify when the final report will be submitted and provide reasons.

[3] A summary in lay language must be included with the final report.

[**Art. 38** Notification and reporting to Swissmedic](https://www.fedlex.admin.ch/eli/cc/2020/553/en#art_38) 

For category C clinical trials, the notifications and reports specified in Articles 35–37 must also be submitted to Swissmedic.

## [Section 3 Reporting in connection with the Use of Radiation Sources and Document Retention](https://www.fedlex.admin.ch/eli/cc/2020/553/en#chap_4/sec_3)


[**Art. 39** Verification, notification and reporting in connection with the use of radiation sources](https://www.fedlex.admin.ch/eli/cc/2020/553/en#art_39) 

[1] For clinical trials with devices capable of emitting ionising radiation and investigations with radiation sources, the sponsor shall verify compliance with the dose constraint specified in Article 45 RPO.

[2] Should the dose constraint be exceeded at any time, the sponsor shall notify the fact to the competent Ethics Committee within 7 days of becoming aware of it.

[3] For category C trials with devices that emit ionising radiation, the notification in accordance with paragraph 2 must also be sent to Swissmedic.

[4] The competent Ethics Committee and Swissmedic may consult the FOPH for expert advice on assessing the calculated or estimated dose and on determining further measures.

[5] For clinical trials in accordance with paragraph 1, the sponsor shall document in the final report all relevant radiological protection information, particularly an estimation of the dose the participants were exposed to; this shall not apply in the case of an exemption from the reporting obligation as specified in Article 14 paragraph 4.

[6] The competent Ethics Committee shall forward the final report to the FOPH.

[**Art. 40** Document retention requirements](https://www.fedlex.admin.ch/eli/cc/2020/553/en#art_40) 

[1] The sponsor must retain all data concerning the clinical trial until the expiry date of the last series of devices used in the trial, but for a minimum of ten years following the conclusion or termination of the clinical trial. The retention period for implantable devices is at least 15 years.

[2] The investigator must retain all documents required to identify and provide post-trial care to participants, as well as all other original data, for at least ten years after the conclusion or termination of the clinical trial. The retention period for implantable devices is at least 15 years.

# [Chapter 5 Transparency](https://www.fedlex.admin.ch/eli/cc/2020/553/en#chap_5)

[**Art. 41** and **42**](https://www.fedlex.admin.ch/eli/cc/2020/553/en#art_41)

# [Chapter 6 Final Provisions](https://www.fedlex.admin.ch/eli/cc/2020/553/en#chap_6)

[**Art. 43** Updating of the annexes](https://www.fedlex.admin.ch/eli/cc/2020/553/en#art_43) 

The Federal Department of Home Affairs may update Annex 1 in line with international or technical developments. Where updates may pose technical barriers to trade, it shall effect such updates by mutual agreement with the Federal Department of Economic Affairs, Education and Research.

[**Art. 44** Amendment of other legislation](https://www.fedlex.admin.ch/eli/cc/2020/553/en#art_44) 

The amendment of other legislation is regulated in Annex 2.

[**Art. 45** Information on directly applicable legal acts of the European Commission](https://www.fedlex.admin.ch/eli/cc/2020/553/en#art_45) 

Swissmedic shall provide on its website information on legal acts of the European Commission that, under the terms of this Ordinance, are directly applicable in Switzerland in the version binding upon the Member States of the European Union.

[**Art. 46** Harmonisation of enforcement](https://www.fedlex.admin.ch/eli/cc/2020/553/en#art_46) 

[1] Swissmedic and the Ethics Committees may prescribe electronic forms and technical procedures for inputting and transmitting documents and for sharing information in the electronic systems in accordance with Article 8.

[2] For the purposes of enforcing this Ordinance, particularly the provision of electronic forms and aids to enforcement, Swissmedic and the Ethics Committees shall comply with the implementing acts adopted by the European Commission under Articles 70, 78 and 81 EU-MDR, specifically in reference to:


|    a. harmonised electronic forms for applications for clinical trials and their assessment, procedures to be performed by Ethics Committees and Swissmedic and for the coordinated assessment procedure;  
|    b. harmonised electronic forms for substantial amendments;  
|    c. harmonised electronic forms for reporting serious adverse events and device deficiencies;  
|    d. the exchange of information between the Member States and Switzerland in the course of communication of intended measures, the termination of a clinical trial for reasons of safety, the withdrawal of an application and refusal to authorise a clinical trial;  
|    e. time limits for reporting serious adverse events and device deficiencies that are notifiable by virtue of their gravity;  
|    f. the requirements of Chapter II of Annex XV to EU-MDR;  
|    g. the coordinated assessment procedure.

[**Art. 47** Cooperation with the European Commission and authorities of the contracting states](https://www.fedlex.admin.ch/eli/cc/2020/553/en#art_47) 

[1] Where provided for by international agreements, Swissmedic shall cooperate with the European Commission and the authorities of the contracting states.

[2] In doing so, Swissmedic shall involve the Ethics Committees in appropriate fashion where their area of responsibility is affected.

[**Art. 48** Transitional provisions for clinical trials approved under previous legislation and involving medical devices](https://www.fedlex.admin.ch/eli/cc/2020/553/en#art_48) 

[1] Approvals for clinical trials of devices issued by the competent Ethics Committee and Swissmedic prior to the entry into force of this Ordinance shall remain valid until their expiry date.

[2] The results of clinical trials of devices that are still in progress when this Ordinance enters into force have to be published in a recognised register in accordance with Article 64 paragraph 1 ClinO within the time limit specified in Article 42.

[3] Where clinical trials in accordance with paragraph 1 undergo substantial amendments, the sponsor must apply for categorisation under Article 6 at the same time.

[**Art. 49** Transitional provisions](https://www.fedlex.admin.ch/eli/cc/2020/553/en#art_49) 

[1] Until Article 8 paragraphs 1, 4 and 5 of this Ordinance comes into force (Art. 50 para. 2), sponsors shall use the following information systems to input and transmit applications, notifications, reports and other information required under this Ordinance:


|    a. the Cantons’ information system in accordance with Article 56*a* HRA for documents and information intended for the competent Ethics Committee;  
|    b. the medical devices information system in accordance with Article 62*c* TPA for documents and information intended for Swissmedic.

[2] Until Article 8 paragraphs 2 and 3 of this Ordinance comes into force (Art. 50 para. 2):


|    a. Swissmedic shall use the medical devices information system in accordance with Article 62*c* TPA to input and transmit decisions and to exchange information with applicants;  
|    b. the competent Ethics Committee shall use the Cantons’ information system in accordance with Article 56*a* HRA for the purposes described in letter a.

[3] Until Articles 41 and 42 of this Ordinance come into force (Art. 50 para. 2), sponsors must register clinical trials in accordance with Articles 64, 65 paragraphs 1 and 3 and 66 and 67 ClinO. They must also publish the results of such clinical trials in a recognised register in accordance with Article 64 paragraph 1 ClinO within the following time limits:


|    a. for concluded category C clinical trials: at the latest before the device is placed on the market or one year after submitting the final report in accordance with Article 37 if the device has not been placed on the market by this point in time;  
|    b. for concluded category A clinical trials and if a trial is terminated or interrupted: immediately after submitting the final report in accordance with Article 37.

[**Art. 50** Commencement](https://www.fedlex.admin.ch/eli/cc/2020/553/en#art_50) 

[1] Subject to the exceptions in paragraph 2, this Ordinance comes into force on 26 May 2021.

[2] Articles 8 paragraph 1–5, 21–31, 41 and 42 come into force at a later date.

# [Annex 1](https://www.fedlex.admin.ch/eli/cc/2020/553/en#annex_1)

(Art. 10 para. 1, 14, 15 para. 6, 16 para. 1, 18 para. 1, 20 para. 5, 23 para. 2)

## [Application documents for the approval procedure for clinical trials](https://www.fedlex.admin.ch/eli/cc/2020/553/en#annex_1/lvl_d1319e61)

### [1 Application documents for category A clinical trials](https://www.fedlex.admin.ch/eli/cc/2020/553/en#annex_1/lvl_d1319e61/lvl_1)

1.1 The application documents specified in Chapter II of Annex XV to EU-MDR, taking account of the amendments to this Annex adopted by the European Commission by means of delegated acts on the basis of Article 70 EU-MDR, must be submitted with the following specification:


|    a. with reference to Chapter II Sections 1.1 and 3.1.2 of Annex XV to EU-MDR (Identification of the sponsor): name, address and contact details of the sponsor and, where the sponsor is not domiciled in Switzerland and does not have a place of business there, its agent in Switzerland;  
|    b. the following information in addition to that required by Chapter II Section 3.1 of Annex XV to EU-MDR for multi-centre clinical trials in Switzerland: name, address and contact details of the coordinating investigator in Switzerland.

1.1bis For clinical trials that are also being conducted or are also due to be conducted in EU or EEA states, any opinions of the relevant foreign Ethics Committee on the clinical trial must be submitted, including any conditions and the reasons for these conditions.

1.2 The following information specified in Chapter II of Annex XV to EU-MDR does not have to be submitted:


|    a. the information in section 1.16;  
|    b. the information in sections 2.3–2.8;  
|    c. the information in section 4.2.

1.3 Swissmedic shall provide on its website information on the delegated acts under section 1.1 that, under the terms of this Ordinance, are directly applicable in Switzerland in the version binding upon the Member States of the EU (Art. 45).

### [2 Application documents for category C clinical trials](https://www.fedlex.admin.ch/eli/cc/2020/553/en#annex_1/lvl_d1319e61/lvl_2)

2.1 The application documents specified in Chapter II of Annex XV to EU-MDR, taking account of the amendments to this Annex adopted by the European Commission by means of delegated acts on the basis of Article 70 EU-MDR, must be submitted with the following specifications for Sections 1.1 and 3.1.2 (Identification of the sponsor): name, address and contact details of the sponsor and, if the sponsor is not domiciled in Switzerland and does not have a place of business there, its agent in Switzerland.

2.1bis For clinical trials that are also being conducted or are also due to be conducted in EU or EEA states, any decisions or opinions of the relevant foreign medical devices supervisory authority and Ethics Committee on the clinical trial must be submitted, including any conditions and the reasons for these conditions.

2.2 If the clinical trial is a multi-centre trial in Switzerland, the name, address and contact details of the coordinating investigator in Switzerland must be provided in addition to the information required under Chapter II Section 3.1.3 of Annex XV to EU-MDR.

2.3 The following information specified in Chapter II of Annex XV to EU-MDR does not have to be submitted:


|    a. the information in section 1.16;  
|    b. the information in section 4.2.

2.4 Swissmedic shall provide on its website information on the delegated acts under section 2.1 that, under the terms of this Ordinance, are directly applicable in Switzerland in the version binding upon the Member States of the EU (Art. 45).

### [3 Application documents for clinical trials in sub-categories C1 and C2 in the coordinated procedure](https://www.fedlex.admin.ch/eli/cc/2020/553/en#annex_1/lvl_d1319e61/lvl_3)

3.1 General part


|    For the general part, the application documents specified in Chapter II of Annex XV to EU-MDR, with the exception of the national part in accordance with Article 23 paragraph 2, taking account of the amendments to this Annex adopted by the European Commission by means of delegated acts on the basis of Article 70 EU-MDR, must be submitted with the following specifications for Sections 1.1 and 3.1.2 (Identification of the sponsor): name, address and contact details of the sponsor and, where the sponsor is not domiciled in Switzerland, its agent in Switzerland. 

3.2 National part


|    For the national part, the application documents specified in Chapter II Sections 1.13, 3.1.3 and 4.2–4.4 of Annex XV to EU-MDR, taking account of the amendments to this Annex adopted by the European Commission by means of delegated acts on the basis of Article 70 EU-MDR, must be submitted with the following specification for Section 3.1.2: For multi-centre trials in Switzerland: name, address and contact details of the coordinating investigator in Switzerland. 

3.3 Swissmedic shall provide on its website information on the delegated acts under section 3.1 and 3.2 that, under the terms of this Ordinance, are directly applicable in Switzerland in the version binding upon the Member States of the EU (Art. 45).

### [4 Additional application documents for clinical trials with devices capable of emitting ionising radiation and for investigations involving radiation sources (Art. 14 para. 1)](https://www.fedlex.admin.ch/eli/cc/2020/553/en#annex_1/lvl_d1319e61/lvl_4)

For clinical trials with devices capable of emitting ionising radiation and for investigations involving radiation sources (Art. 14 para. 1), the following additional information and documents must be submitted:


|    a. information on significant radiation protection aspects, particularly a calculation or estimation of the effective dose-equivalent, the doses absorbed by the organs and, if applicable, the doses absorbed by the tumours;  
|    b. the necessary permits in accordance with Article 28 of the Radiological Protection Act of 22 March 1991.

### [5 Additional application documents for category C clinical trials with devices capable of emitting ionising radiation and for clinical trials involving investigations with radiation sources and requiring the comments of the FOPH in accordance with Article 14 paragraph 2](https://www.fedlex.admin.ch/eli/cc/2020/553/en#annex_1/lvl_d1319e61/lvl_5)

For category C clinical trials with devices capable of emitting ionising radiation (Art. 18) and investigations involving radiation sources that require the comments of the FOPH in accordance with Article 14 paragraph 2, the following information must be submitted in addition to the information listed under number 4:


|    a. if applicable, information on the properties, specifically the pharmacokinetics, quality, stability, radiochemical purity and radionuclide purity;  
|    b. for authorised radiopharmaceuticals: the information for healthcare professionals;  
|    c. for non-authorised radiopharmaceuticals: information on the manufacturing process and quality control of the radiopharmaceutical, the names of the people responsible for both and their professional qualifications;  
|    d. the names of the people responsible for the use of the radiopharmaceutical on humans and their professional qualifications;  
|    e. information required by the FOPH form for clinical trials with radiopharmaceuticals or radiolabelled substances.

# [Annex 2](https://www.fedlex.admin.ch/eli/cc/2020/553/en#annex_2)

(Art. 44)

## [Amendments to other legislation](https://www.fedlex.admin.ch/eli/cc/2020/553/en#annex_2/lvl_d1319e69)

The following are amended as follows:

...

